Information Provided By:
Fly News Breaks for March 4, 2020
MRNA
Mar 4, 2020 | 20:19 EDT
Piper Sandler analyst Edward Tenthoff keeps his Overweight rating and $32 price target on Moderna, saying the company's "Manufacturing & Digital Day" presentation showcased its "overwhelming advantages" in mRNA drug discovery, development, and manufacturing, with ability to produce over 75g batches at a cost that is 69% lower than last year. The analyst notes that this capability has allowed Moderna to manufacture CMV vaccine mRNA-1647 in its ongoing phase 2 study and also gives it the speed to ship coronavirus vaccine mRNA-1273 for clinical testing in just 42 days.
News For MRNA From the Last 2 Days
MRNA
May 19, 2022 | 09:55 EDT
Notable gainers among liquid option names this morning include Synopsys (SNPS) $292.33 +19.76, Live Nation (LYV) $90.59 +5.20, Moderna (MRNA) $143.87 +6.16, Expedia (EXPE) $124.71 +4.56, and Freeport McMoRan (FCX) $36.45 +1.11.